Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean octinoxate and titanium dioxide?
Displaying drugs 13951 - 13975 of 14604 in total

5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE

Experimental

1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA

Experimental

4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE

Experimental

Zopolrestat

Experimental

PKI-179

PKI-179 has been used in trials studying the treatment of Advanced Malignant Solid Tumors.
Investigational

Neocitrullamon

Experimental

Beta-hydroxyfentanyl

Experimental
Illicit

(4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE

Experimental

4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE

Experimental

4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide

Experimental

(3R,4S)-1-[(4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL]-4-[(METHYLSULFANYL)METHYL]PYRROLIDIN-3-OL

Experimental

Cenerimod

Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Investigational

Rimiterol

Experimental

Trelagliptin

Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").
Investigational

Motexafin lutetium

Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.
Investigational

1'-Deazo-Thiamin Diphosphate

Experimental

4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine

Experimental

Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine

Experimental

Verucerfont

Verucerfont has been used in trials studying the treatment of Congenital Adrenal Hyperplasia.
Investigational

beta-Apopicropodophyllin

beta-Apopicropodophyllin is a component of the freshwater plant Micranthemum umbrosum.
Experimental

(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene

(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene is a solid. This compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. Known drug targets of (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and naphthalene 1,2-dioxygenase subunit alpha.
Experimental
Matched Description: … (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and …

Clocapramine

Clocapramine is an atypical antipsychotic of the imidobenzyl class which was introduced in Japan in 1974 for the treatment of schizophrenia. In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic. Clocapramine has been implicated in at least one strange death,...
Experimental
Matched Description: … to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and …

(3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol

(3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol is a solid. This compound belongs to the benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. This substance is known to target disintegrin and metalloproteinase domain-containing protein 17.
Experimental
Matched Description: … This substance is known to target disintegrin and metalloproteinase domain-containing protein 17. …

Elinzanetant

Elinzanetant is under investigation in clinical trial NCT05099159 (A Study to Learn More About How Well Elinzanetant Works and How Safe It Is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)).
Investigational
Matched Description: … investigation in clinical trial NCT05099159 (A Study to Learn More About How Well Elinzanetant Works and …

REP8839

REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Displaying drugs 13951 - 13975 of 14604 in total